论文信息 - EDITORIAL COMMENT. - 字舞流文

EDITORIAL COMMENT.

O. Sartor | C. Bennett

[1] D. Agarwal,et al. Cost-Effectiveness of 90-Day Single-Use Flexible Cystoscope Trial: Single Center Micro-Costing Analysis and User Satisfaction. , 2022, Urology.

[2] Lisa Rosenbaum. Metric Myopia - Trading Away Our Clinical Judgment. , 2022, The New England journal of medicine.

[3] Ravi B. Parikh,et al. The Oncology Care Model at 5 Years-Value-Based Payment in the Precision Medicine Era. , 2021, JAMA oncology.

[4] Ryan D. Ross,et al. Adoption of Abiraterone and Enzalutamide by Urologists. , 2019, Urology.

[5] O. Sartor,et al. Health-related quality of life in advanced prostate cancer and its treatments: biochemical failure and metastatic disease populations. , 2015, Clinical genitourinary cancer.

[6] Kurt Miller,et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[7] A. Sartor,et al. Urologists and oncologists: adapting to a new treatment paradigm in castration‐resistant prostate cancer (CRPC) , 2012, BJU international.

[8] Arturo Molina,et al. Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[9] J. Ioannidis. Why Most Published Research Findings Are False , 2005, PLoS medicine.

[10] Adam G. Tennant,et al. The Anti‐Androgen Transfer , 2000 .